Cancer Alliance access to National Cancer Waiting Times Monitoring Data Set (NCWTMDS) from the Cancer Wait Times (CWT) System
South East London Cancer Alliance · Network
Expired The latest version ended on 11 January 2025. The September 2026 register still lists the agreement, but its term has passed.
- Reference
- DARS-NIC-204554-Y7F3H
- Latest version
- v3.2
- Term of latest version
- 12 January 2022 to 11 January 2025
- Start date
- 1 February 2019
- Data controller
- Sole Data Controller
- Commercial purposes
- No
- Sublicensing
- No
- Files released to date
- 0
Data controllers
Why the data was released
Objective for processing
This agreement is for the South East London Cancer Alliance (SELCA) to access Cancer Waiting Times data. The purpose for which the data is processed under this agreement is determined by the cancer alliance.
However as the Cancer Alliance is not a legal entity, as staff are substantially employed by
Guy's and St Thomas' NHS Foundation Trust, who are therefore the lead organisation, and the data controller who processes data. In this agreement therefore, all references to accessing patient level data refer to the legal entity – Guy's and St Thomas' NHS Foundation Trust. SELCA decision making, including the determination of the purpose for processing this data, is driven by its own board which includes all partners in the SEL geography (trusts, CCG, Primary care, ICS). All decisions of the board are finalised on by board chairs, Managing Director and Clinical Director who are both employees of the Trust and sign off all strategic pieces of work.
Improvements for Cancer patients
The independent Cancer Taskforce set out an ambitious vision for improving services, care and outcomes for everyone with Cancer: fewer people getting Cancer, more people surviving Cancer, more people having a good experience of their treatment and care, whoever they are and wherever they live, and more people being supported to live as well as possible after treatment has finished.
Cancer Alliances
Cancer Alliances, which have been set up across England, are key to driving the change needed across the country to achieve the Taskforces vision. Bringing together local clinical and managerial leaders from providers and commissioners who represent the whole Cancer pathway, Cancer Alliances provide the opportunity for a different way of working to improve and transform Cancer services. Cancer Alliance partners will take a whole population, whole pathway approach to improving outcomes across their geographical footprints building on their relevant Sustainability and Transformation Plans (STPs). They will bring together influential local decision-makers and be responsible for directing funding to transform services and care across whole pathways, reducing variation in the availability of good care and treatment for all people with Cancer, and delivering continuous improvement and reduction in inequality of experience. They will particularly focus on leading transformations at scale to improve survival, early diagnosis, patient experience and long term quality of life. Successful delivery will be shown in improvements in ratings in the Clinical Commissioning Group (CCG) Improvement and Assessment Framework (IAF), including, importantly, in the 62 day wait from referral to first treatment standard.
Cancer Wait Times (CWT) system
The Cancer Wait Times (CWT) system collects and validates the National Cancer Waiting Times Monitoring Data Set (NCWTMDS), allowing performance to be measured against operational Cancer standards. Data is validated and records merged to the same pathway to cover the period from referral to first definitive treatment for Cancer and any additional subsequent treatments.
The CWT system then determines whether the operational standard(s) that apply were met or not for the patient and the accountable provider(s). The CWT system holds NCWTMDS in a series of pre-aggregated static reports. These reports are available monthly and quarterly data (aligned with the National Statistics for Cancer Waiting Times published by NHS England). Users can query the CWT system to generate reports to feedback on the progress towards meeting these targets.
Cancer alliances are also created to drive improvement in cancer outcomes. Align with the improvement trajectory set for cancer survival (also part of CCG IAF), cancer alliances are set to deliver the Faster Diagnostic Standards (FDS) from April 2021 (delayed from April 2020). FDS is part of CWT dataset, referring to the duration between urgent GP referral to patients being told whether they have a cancer diagnosis or not.
The National Cancer Programme has confirmed that FDS, along with 62-day wait, will be key metrics within the 10 year NHS Plan that Cancer Alliances will be held accountable to. Thus without access to the data as outlined in this request, the Cancer Alliance will not be able to deliver work programme as outlined by the National Cancer Programme. The Cancer Alliance will directly access the Cancer Waiting Times System on behalf of alliance member trusts and CCGs
South East London Cancer Alliance
Guys and St Thomas NHS Trust will directly access the Cancer Waiting Times System on behalf of South East London Cancer Alliance across South East London, which covers a population of 1.9 million people.
Guys and St Thomas NHS Trust works with health organisations across South East London including 3 acute providers, and 6 clinical commissioning groups.
Acute Providers
•Guys and St Thomas NHS Trust
•King's College Hospital NHS Foundation Trust
•Lewisham and Greenwich NHS Trust
CCGs
•NHS South East London CCG
Data access
The CWT system provides the Data Controller / Processor representing each Cancer Alliance, with access to the following;
a) Aggregate reports (which may include unsuppressed small numbers)
b) Pseudonymised record level data - users can directly download this data from the CWT system
c) I-View Plus tool
The organisation will only access patient records which fall within the Cancer Alliances' footprint of responsibility based on the patients' CCG of responsibility.
A) Aggregate reports including small numbers
Aggregate data is available in the form of reports at Provider (Trust) and Clinical Commissioning Group (CCG) level. Small numbers may be included in the aggregate data reports and are essential for analyses carried out by lead organisations.
Investigating breaches
The Data Controller routinely monitors performance and standards using the CWT system, particularly in relation to breaches of the 62 day wait target. Due to the large number of potential Trust/CCG combinations, breach counts could result in small numbers as in some cases there are less than 6 breaches in a whole year. Given that financial penalties are linked to target breaches counts must accurately reflect the true percentage without suppression.
Mitigating risk of re-identification
Risk of disclosure is minimised as the dataset does not include patient demographics (increasing risk of re-identification) that may allow users to identify an individual e.g. there are no age, ethnic categories or geographic breakdowns based on patient postcode.
Additionally, the aggregation categories are such that the data is not at a lesser granular level e.g. the source NCWTMDS data collects information at ICD diagnosis code level, but the CWT system aggregates at tumour group level e.g. Head & Neck, Upper GI, Lower GI, Breast etc.
B) Pseudonymised record level extracts
Approved users will access record level pseudonymised data which includes the system generated pseudo CWT patient ID. Any record level data extracted from the system will not be processed outside of the authorised users of the system.
C) i-View Plus
iView Plus uses cube functionality to allow lead organisations to produce graphs, charts and tabulations from the data through the construction of queries. The data in iView plus is split by operational standard being measured and can then be analysed against a range of dimensions collected in the data and measures such as count, percentage and median. The outputs of iView Plus are aggregate, and no record level data can be obtained, however some queries may result in small numbers and these currently have limited disclosure control applied, see A) for further explanation. iView Plus holds published data, the lowest organisational granularity is trust level, data can also be aggregated to CCG level and other health hierarchies.
The Cancer Alliance will use the data to both monitor and improve performance against the Cancer Waiting Time standards and to inform wider Cancer pathway improvements.
The Cancer Alliance's use of the data will fall into two separate categories, each requiring different levels of suppression, and onward sharing both within the Cancer Alliance and with wider NHS stakeholders;
Purpose One - Aggregate local reports
Generation of routine Cancer Waiting Times reports at Provider (Trust) or CCG level. Lead organisations will access a summary of the totals for the Providers (Trust) and CCG's that are treating cancer patients where they have a commissioning responsibility for that patient (based on the CCG they are aligned to). This analysis would then be shared with the providers and commissioners and used to inform service improvement by providing benchmarked comparable data. The format of this report would be in a tabulated or graphical form (i.e. not record level) but may contain small numbers. An example of where small numbers would not be suppressed would be in relation to cases of breaches against a standard where small numbers would be essential to ensure the report is meaningful.
Examples of this type of analysis include:
a. Comparative Cancer Waiting Times performance at tumour group and individual tumour site (i.e. ICD10 code) level for Trusts and CCGs across the geography
b. Analysis of Cancer Waiting Times performance by treatment modality
c. Grouping length of waits for standards
d. Analysis of derived breach reason fields to identify trends in reasons for delays
e. To provide assurance through comparative analysis (e.g. orphan record identification, active monitoring proportions and validation of waiting list adjustments entered)
f. Analysis of flows of patients including analysis by provider trust site
g. Reviewing waits between surgery and radiotherapy for Head and Neck Cancer patients with a maximum recommended wait of 6 weeks
h. Reviewing routes to diagnosis of patients
i. Quantifying treatment volumes by provider organisation including analysis treatment rates
Purpose Two - Sharing of record level data with providers and commissioners responsible for direct patient care for that patient. This will be for local audit purposes.
The two broad purposes for this would be;
1) To support audit work
2) Investigate individual outliers to the national standards
Pathway analysis will be undertaken, identifying trends in reasons for breaches. The analysis will inform system wide pathway improvements and compliance to the national standards. Examples of potential changes to achieve this could be to support trusts in additional resources and processes and also to facilitate discuss between trusts for example in reaching agreement for diagnostics between trusts.
Examples of the types of reasons for this include;
a. Patients waiting excessively long period of time to seen of received treatment
b. Identification of 28 day standard exceptions - National guidance states patients who are diagnosed with cancer should be informed face to face, this would highlights numbers of patients who are not told in person by provider
c. Audits to review orphan records which require local providers to review local patients records
Record level data (pseudonymised) will be shared via NHS.net email accounts and access will be controlled by password protecting all files.
Processing activities
Access to the Cancer Wait Times (CWT) System will enable Cancer Alliances to undertake a wide range of locally determined and locally-specific analyses to support the Cancer Taskforce vision for improving services, care and outcomes for everyone with Cancer.
Only the lead organisation will directly access or download extracts from the Cancer Waiting Times system. Role Based Access Control prevents access to data downloads to employees outside of the analytical team responsible for producing outputs.
The CWT system is hosted by NHS Digital, access to and usage of the system is fully auditable. Users must comply with the use of the data as specified in this agreement. The CWT system complies with the requirements of NHS Digital Code of Practice on Confidential Information, the Caldicott Principles and other relevant statutory requirements and guidance to protect confidentiality.
Access to the CWT system will be granted to individual users only when a valid Data Usage Certificate (DUC) form is submitted to NHS Digital via the lead organisations Senior Information Risk Officer (SIRO), and where there is a valid Data Sharing Agreement between the lead organisation and NHS Digital.
Approved users will log into the system via a secure connection and will use a Single Sign-On (users are prompted to create a unique username and password).
Approved users will access:
a) Aggregate reports (which may include unsuppressed small numbers)
b) Pseudonymised record level data - users can directly download this data from the CWT system
c) I-View Plus tool (aggregated - access to produce graphs, charts/tabulations from the data through the construction of queries). This will give users access to run bespoke analysis on pre-defined measures and dimensions. It delivers the same data that is available through the reports and record level downloads (i.e. it will not contain patient identifiable data).
Any record level data extracted from the system will not be processed outside of the Data Controller or Data Processor unless otherwise specified in this agreement. Following completion of the analysis the record level data will be securely destroyed.
Users are not permitted to upload data into the system.
Data will only be shared with other members of the cancer alliance in aggregated form (without small number suppression).
Aggregate data/ graphical outputs may be shared via e-mail; for example as part of Alliance meeting papers.
Where record level data is shared with individual trusts these are shared only with trust(s) who were involved in the direct care of the patient, only via NHS.net email accounts.
As part of partnership working to improve Cancer Waiting Times performance, outputs may be shared with national/regional bodies including NHS Improvement and NHS England.
Training on the CWT system is not required as it is a data delivery system and it does not provide functionality to conduct bespoke detailed analysis. User guides are available for further assistance.
Access to the CWT system data is restricted to Cancer Alliance employees who are substantively employed by the Data Controller in fulfilment of their public health function.
The Cancer Alliances will use the data to produce a range of quantitative measures (counts, crude and standardised rates and ratios) that will form the basis for a range of statistical analyses of the fields contained in the supplied data.
Typical uses will include:
1) Analysis to support delivery of Cancer Waiting Times standard and identify variation, including clinical discussions to improve patient pathways
a. Comparative Cancer Waiting Times performance at tumour group and individual tumour site (i.e. ICD10 code) level for Trusts and CCGs. As well as the percentage of 62 Day performance, we will also need to look at number of activities, total numbers of patients treated, number of patients treated before and after Day 62
b. Analysis of Cancer Waiting Times performance by treatment modality to inform discussions
c. Grouping length of waits for standards to inform discussions on going beyond constitutional standards (e.g., activity and breach share by first seen trust and treatment trust, and by tumour site)
d. Analysis of derived breach reason fields to identify trends in reasons for delays.
e. To provide assurance through comparative analysis (e.g. orphan record identification, active monitoring proportions and validation of waiting list adjustments entered)
f. Analysis of flows of patients including analysis by provider trust site, by tumour site (e.g. median pathway durations, and the ability to track changes over time with "run charts" as per NHS Improvement requirements)
g. Outlier identification including exceptionally long waits to inform individual queries to providers
2) Cancer Waits analysis (not directly linked to constitutional standards) for the aim of identifying variation which may impact Cancer patients outcomes or patient experience. Examples for use of the data may include reviewing waits between surgery and radiotherapy for Head and Neck cancer patients with a maximum recommended wait of 6 weeks and using the data source to validate surgical numbers by provider trust.
Expected output
Outputs fall into the following categories:
1) Analysis to support delivery of Cancer Waiting Times standard and identify variation, including clinical discussions to improve patient pathways
a. Comparative Cancer Waiting Times performance at tumour group and individual tumour site (i.e. ICD10 code) level for Trusts and CCGs.
b. Analysis of Cancer Waiting Times performance by treatment modality to inform discussions
c. Grouping length of waits for standards to inform discussions on going beyond constitutional standards
d. Analysis of derived breach reason fields to identify trends in reasons for delays.
e. To provide assurance through comparative analysis (e.g. orphan record identification, active monitoring proportions and validation of waiting list adjustments entered)
f. Analysis of flows of patients including analysis by provider trust site
g. Analysis of flows of patients across geography including analysis by tumour groups where specialist treatments are required only to be delivered by designated centres, aligning to Improving Outcome Guidance (NICE IOG)
h. Outlier identification including exceptionally long waits to inform individual queries to providers
2) Cancer Waits analysis (not directly linked to constitutional standards) for the aim of identifying variation which may impact Cancer patients outcomes or patient experience. Examples for use of the data may include reviewing waits between surgery and radiotherapy for Head and Neck cancer patients with a maximum recommended wait of 6 weeks and using the data source to validate surgical numbers by provider trust.
Expected measurable benefits
1) Benefits type: Supporting delivery of CWT standards
The Cancer Waiting Times standards are key operational standards for the NHS, which aim to reduce the waits for diagnosis and treatment for Cancer patients, which will support improvements to survival rates and improve patient experience. This includes the new 28 day faster diagnosis standard being introduced as a standard from April 2021.
A key enabler to achieve these standards, and thus improve survival and patient experience is the role of Cancer Alliances locally to work with providers and commissioners to improve patient pathways. Access to the Cancer Waiting Times data as detailed in the above will enable Cancer Alliances to have informed discussions and allocate resources optimally to improve performance against these standards. It will also enable Cancer Alliances to work with local providers and commissioners to identify outliers against the standards, and mitigate the risk of similar delays for other patients.
Improvement would be expected on an on-going basis with standards already in place for nine standards:-
2 week wait urgent GP referral- 93%
2 week wait breast symptomatic -93%
31 day 1st treatment - 96%
31 day subsequent surgery-94%
31 day subsequent drugs-98%
31 day subsequent radiotherapy-94%
62 day (GP) referral to 1st treatment-85%
62 day (screening ) referral to 1st treatment-90%
62 day upgrade to 1st treatment locally agreed standard
In addition this access and use of data will be key in delivering the new 28 day faster diagnosis standard being
introduced from April 2021 (delayed from April 2020). Trusts are asked to ensure high level of data completeness for this item in 2019/20.
2) Benefits type: Improvements beyond constitutional standards
This access and resulting analysis will enable Cancer Alliances to undertake local analysis beyond the Cancer
Waiting times operational standards to support improvements to Cancer patients pathways beyond those already achieved by improving performance against standard set. This could include reviewing times between treatments, or treatment rates. The overall aim of this type of additional analysis would be to support improvements to Cancer patients survival and experience.
The Cancer Taskforce recommendation set out a number of ambitions to be met nationally and locally by 2020 including improving 1 year survival for Cancer to 75%, and improving the proportions of patients staged 1 or 2 to 62%. For both of these improvements to the diagnostic and treatment pathways are key, and require Cancer Alliances to be able to analyse the Cancer Waiting Times dataset to identify sub-optimum pathway and resulting improvements.
The overarching aim of all future analysis/outputs is to inform priorities and potential investment to improve Cancer pathways including reducing Cancer incidence and mortality, improving Cancer survival, improving patient experience, improving service efficiency and meeting national constitution standards relating to Cancer patients.
Benefits reported so far
Access to the National Cancer Waiting Times (CWT) data via the NHS Digital portal has given the South East London (SEL) Cancer Alliance the ability to access granular CWT data with immediacy which has been particularly beneficial for the faster diagnosis standard (FDS) data from the start of the financial year. This has allowed the South East London Cancer Alliance to immediately understand performance and drivers, using locally developed dashboarding leveraging off the national CWT data, across South East London (SEL). This has allowed an understanding for areas of focus for the Cancer Alliance FDS Implementation Lead, which has led to improvements in performance in Breast and Head and Neck pathways and local discussion with both trusts and commissioners via the cancer alliance infrastructure (tumour level boards, provider boards) on how to improve pathways to meet the FDS standard, and is critical to improving challenged areas such as Colorectal, Gynaecology, and Urology
By breaking down the data, for example by sub tumour speciality and clinical commissioning group (CCG), the SEL Cancer Alliance can understand the volumes in throughput of patients by geography and specific tumour. In addition, the associated waiting times can be compared to other clinical indicators, such as numbers of stage 1 and 2 cancers, as well as identifying specific sub-speciality pathways that are outliers against the standards in specific areas of the alliance geography, and can identify disparity in performance between SEL providers for Urology cancer. Using CWT data can identify areas of inequality, ensure tumour level work plans include reducing inequality within the alliance geography and increasing patient equity of service.
NHS Digital CWT was key to SELCA demonstrating pathway outliers when looking at a range of statistical days on the pathway (median, percentile) when looking at all indicators for Prostate, Lung, and Gynaecology split by shared and internal pathways, grouped ICD10 codes, and across years and quarters to compare current performance with historical baselines. These are important pieces of work that are updated regularly to aid discussion on continuous improvement between key stakeholders
By looking at data at the linked provider and commissioner level we've been able to look at 2WW and treatment rate in more detail to understand the shape of recovery whilst we are still in the pandemic. We were able to identify tumour groups that were experiencing greater levels of referral into the system from outside of South East London which allowed commissioners to discuss with their counterparts why some of the non-established routes were happening and support their resolution
Datasets on the latest version
Legal basis for provision: Health and Social Care Act 2012 - s261 - 'Other dissemination of information'
| Dataset | Type of data | Sensitivity | Frequency | Confidential data |
|---|---|---|---|---|
| National Cancer Waiting Times Monitoring DataSet (NCWTMDS) | Anonymised - ICO Code Compliant | Sensitive | System Access | Does not include the flow of confidential data |
Files released
Files released counts only files released externally by DARS. Access granted in NHS England's own systems, such as its Secure Data Environment, is not included.
No files recorded as released under this agreement.
Version history
The register lists each renewal of this agreement as a separate row. This site has 4 versions.
DARS-NIC-204554-Y7F3H-v3.2 12 January 2022 to 11 January 2025
- Title
- Cancer Alliance access to National Cancer Waiting Times Monitoring Data Set (NCWTMDS) from the Cancer Wait Times (CWT) System
- Commercial
- No
- Sublicensing
- No
- Datasets
- 1
- Files released
- 0
Datasets: National Cancer Waiting Times Monitoring DataSet (NCWTMDS)
What changed from DARS-NIC-204554-Y7F3H-v2.1
Text removed is struck through; text added is underlined. Unchanged paragraphs are summarised rather than repeated.
| Field | Was | Became |
|---|---|---|
| Start date | 2022-01-12 | |
| End date | 2025-01-11 |
Objective for processing
This agreement is for the South East London Cancer Alliance to access Cancer Waiting Times data. However, the Cancer Alliance is not a legal entity - its staff (and those accessing the Cancer Waiting Times data) are substantively employed by Guys and St Thomas' NHS Trust . Guys and St Thomas' NHS Trust is therefore the lead organisation, and the data controller who processes data. In this agreement, therefore, all references to accessing the data refer to the legal entity - Guys and St Thomas NHS Trust.
This agreement is for the South East London Cancer Alliance (SELCA) to access Cancer Waiting Times data. The purpose for which the data is processed under this agreement is determined by the cancer alliance.
However as the Cancer Alliance is not a legal entity, as staff are substantially employed by
Guy's and St Thomas' NHS Foundation Trust, who are therefore the lead organisation, and the data controller who processes data. In this agreement therefore, all references to accessing patient level data refer to the legal entity – Guy's and St Thomas' NHS Foundation Trust. SELCA decision making, including the determination of the purpose for processing this data, is driven by its own board which includes all partners in the SEL geography (trusts, CCG, Primary care, ICS). All decisions of the board are finalised on by board chairs, Managing Director and Clinical Director who are both employees of the Trust and sign off all strategic pieces of work.
[3 paragraphs unchanged]
Cancer Alliances, which have been set up across England, are key to driving the change needed across the country to achieve the
Taskforce’s
Taskforces
vision. Bringing together local clinical and managerial leaders from providers and commissioners
[28 words unchanged]
a whole population, whole pathway approach to improving outcomes across their geographical
‘footprints’,
footprints
building on their relevant Sustainability and Transformation Plans (STPs). They will bring
[48 words unchanged]
leading transformations at scale to improve survival, early diagnosis, patient experience and
long-term
long term
quality of life. Successful delivery will be shown in improvements in ratings
[12 words unchanged]
importantly, in the 62 day wait from referral to first treatment standard.
https://www.england.nhs.uk/publication/ccg-iaf-methodology-manual/
[3 paragraphs unchanged]
Cancer alliances are also created to drive improvement in cancer outcomes. Align with the improvement trajectory set for cancer survival (also part of CCG IAF), cancer alliances are set to deliver the Faster Diagnostic Standards (FDS) from April 2021 (delayed from April 2020). FDS is part of CWT dataset, referring to the duration between urgent GP referral to patients being told whether they have a cancer diagnosis or not.
The National Cancer Programme has confirmed that FDS, along with 62-day wait, will be key metrics within the 10 year NHS Plan that Cancer Alliances will be held accountable to. Thus without access to the data as outlined in this request, the Cancer Alliance will not be able to deliver work programme as outlined by the National Cancer Programme. The Cancer Alliance will directly access the Cancer Waiting Times System on behalf of alliance member trusts and CCGs
[8 paragraphs unchanged]
• Lambeth CCG
•NHS South East London CCG
• Southwark CCG
• Lewisham CCG
• Greenwich CCG
• Bexley CCG
• Bromley CCG
[1 paragraph unchanged]
The CWT system provides
one organisation (the lead organisation)
the Data Controller / Processor
representing each Cancer Alliance, with access to the following;
[3 paragraphs unchanged]
Lead organisations
The organisation
will only access patient records which fall within the Cancer Alliances' footprint of responsibility based on the patients' CCG of responsibility.
This Cancer Alliance is limited to South East London Cancer Patients.
[1 paragraph unchanged]
Aggregate data is available in the form of reports at Provider (Trust) and Clinical Commissioning Group (CCG) level.
Small numbers may be included in the aggregate data reports and are essential for analyses carried out by lead organisations.
Small numbers may be included in the aggregate data reports and are essential for analyses carried out by lead organisations.
[1 paragraph unchanged]
Guys and St Thomas' NHS Trust
The Data Controller
routinely
monitor
monitors
performance and standards using the CWT system, particularly in relation to breaches
[42 words unchanged]
to target breaches counts must accurately reflect the true percentage without suppression.
[2 paragraphs unchanged]
Additionally, the aggregation categories are such that the data is not at
[13 words unchanged]
diagnosis code level, but the CWT system aggregates at tumour group level
–
e.g. Head & Neck, Upper GI,
lower
Lower
GI, Breast etc.
[1 paragraph unchanged]
Lead organisations
Approved users
will access record level pseudonymised data which includes the system generated pseudo CWT patient ID.
Any record level data extracted from the system will not be processed outside of the authorised users of the system.
Any record level data extracted from the system will not be processed outside of the authorised users of the system.
[1 paragraph unchanged]
iView Plus uses cube functionality to allow lead organisations to produce graphs,
[69 words unchanged]
these currently have limited disclosure control applied, see A) for further explanation.
iView Plus holds published data, the lowest organisational granularity is trust level, data can also be aggregated to CCG level and other health hierarchies.
iView Plus holds published data, the lowest organisational granularity is trust level, data can also be aggregated to CCG level and other health hierarchies.
The Cancer Alliance will use the data to both monitor and improve performance against the Cancer Waiting Time standards and to inform wider Cancer pathway improvements.
Guys and St Thomas' NHS Trust will use the data to both monitor and improve performance against the Cancer Waiting Time standards and to inform wider Cancer pathway improvements.
The Cancer Alliance's use of the data will fall into two separate categories, each requiring different levels of suppression, and onward sharing both within the Cancer Alliance and with wider NHS stakeholders;
Guys and St Thomas' NHS Trust use of the data will fall into two separate categories, each requiring different levels of suppression, and onward sharing both within the Cancer Alliance and with wider NHS stakeholders;
[1 paragraph unchanged]
Generation of routine Cancer Waiting Times reports at Provider (Trust) or CCG level.
Guys and St Thomas' NHS Trust
Lead organisations
will access a summary of the totals for the Providers (Trust) and
[88 words unchanged]
where small numbers would be essential to ensure the report is meaningful.
[4 paragraphs unchanged]
d. Analysis of
free text and
derived breach reason fields to identify trends in reasons for delays
[5 paragraphs unchanged]
Purpose Two - Sharing of record level data
(including free text breach reasons)
with providers and commissioners responsible for direct patient care for that patient. This will be for local audit purposes.
[6 paragraphs unchanged]
b. Free text breach reasons identifying areas of concern which require more detail or clarification from provider
b. Identification of 28 day standard exceptions - National guidance states patients who are diagnosed with cancer should be informed face to face, this would highlights numbers of patients who are not told in person by provider
c. Identification of 28 day standard exceptions - National guidance states patients who are diagnosed with cancer should be informed face to face, this would highlights numbers of patients who are not told in person by provider
c. Audits to review orphan records which require local providers to review local patients records
d. Audits to review orphan records which require local providers to review local patient’s records
[1 paragraph unchanged]
Processing activities
Access to the Cancer Wait Times (CWT) System will enable Cancer Alliances to undertake a wide range of
locally-determined
locally determined
and locally-specific analyses to support the Cancer Taskforce vision for improving services, care and outcomes for everyone with Cancer.
Only the lead organisation
Guys and St Thomas' NHS Trust
will directly access
or download extracts from
the Cancer Waiting Times system.
Extracts can be downloaded and will be stored on the Guys and St Thomas' NHS Trust servers.
Role Based Access Control prevents access to data downloads to employees outside of the analytical team responsible for producing
outputs; the South East London Accountable Cancer Network informatics team.
outputs.
[2 paragraphs unchanged]
Approved users will log into the system via
an N3
a secure
connection and will use a Single Sign-On (users are prompted to create a unique username and password).
Guys and St Thomas' NHS Trust
Approved
users will access:
[3 paragraphs unchanged]
Any record level data extracted from the system will not be processed outside of
Guys and St Thomas' NHS Trust
the Data Controller or Data Processor
unless otherwise specified in this agreement. Following completion of the analysis the record level data will be securely destroyed.
[1 paragraph unchanged]
Data will only be available for the Providers (Trust) and CCG's that are treating cancer patients where they have a commissioning responsibility for that patient (based on the CCG that this Cancer Alliance is aligned to).
Data will only be shared with other members of the cancer alliance in aggregated form (without small number suppression).
The data will only
Aggregate data/ graphical outputs may
be shared
with other members of the Cancer Alliance in the format described in purpose 1 and purpose 2 of this agreement. The primary method for sharing outputs is
via e-mail; for example as part of Alliance meeting papers.
[1 paragraph unchanged]
As part of partnership working to improve Cancer Waiting Times performance, outputs may be shared with
national/ regional
national/regional
bodies including
the South East London sustainability
NHS Improvement
and
transformation partnership (STP). Data will only be shared as described in purpose one and purpose two of this agreement and where recipient organisations hold a valid Data Sharing Agreement with
NHS
Digital to access Cancer Waiting Times data.
England.
[5 paragraphs unchanged]
a. Comparative Cancer Waiting Times performance at tumour group and individual tumour site (i.e. ICD10 code) level for Trusts and CCGs.
As well as the percentage of 62 Day performance, we will also need to look at number of activities, total numbers of patients treated, number of patients treated before and after Day 62
[1 paragraph unchanged]
c. Grouping length of waits for standards to inform discussions on going beyond constitutional standards
(e.g., activity and breach share by first seen trust and treatment trust, and by tumour site)
d. Analysis of
free text and
derived breach reason fields to identify trends in reasons for delays.
[1 paragraph unchanged]
f. Analysis of flows of patients including analysis by provider trust
site, by tumour
site
(e.g. median pathway durations, and the ability to track changes over time with "run charts" as per NHS Improvement requirements)
[1 paragraph unchanged]
2) Cancer Waits analysis (not directly linked to constitutional standards) for the aim of identifying variation which may impact Cancer
patient’s
patients
outcomes or patient experience. Examples for use of the data may include
[20 words unchanged]
and using the data source to validate surgical numbers by provider trust.
Expected output
[5 paragraphs unchanged]
d. Analysis of
free text and
derived breach reason fields to identify trends in reasons for delays.
[2 paragraphs unchanged]
g. Outlier identification including exceptionally long waits to inform individual queries to providers
g. Analysis of flows of patients across geography including analysis by tumour groups where specialist treatments are required only to be delivered by designated centres, aligning to Improving Outcome Guidance (NICE IOG)
2) Cancer Waits analysis (not directly linked to constitutional standards) for the aim of identifying variation which may impact Cancer patient’s outcomes or patient experience. Examples for use of the data may include reviewing waits between surgery and radiotherapy for Head and Neck cancer patients with a maximum recommended wait of 6 weeks and using the data source to validate surgical numbers by provider trust.
h. Outlier identification including exceptionally long waits to inform individual queries to providers
The overarching aim of all future analysis/outputs is to inform priorities and potential investment to improve Cancer pathways including reducing Cancer incidence and mortality, improving Cancer survival, improving patient experience, improving service efficiency and meeting national constitution standards relating to Cancer patients.
2) Cancer Waits analysis (not directly linked to constitutional standards) for the aim of identifying variation which may impact Cancer patients outcomes or patient experience. Examples for use of the data may include reviewing waits between surgery and radiotherapy for Head and Neck cancer patients with a maximum recommended wait of 6 weeks and using the data source to validate surgical numbers by provider trust.
Expected measurable benefits
[1 paragraph unchanged]
The Cancer Waiting Times standards are key operational standards for the NHS,
[28 words unchanged]
28 day faster diagnosis standard being introduced as a standard from April
2020.
2021.
[2 paragraphs unchanged]
•
2 week wait urgent GP
referral –
referral-
93%
•
2 week wait breast symptomatic
– 93%
-93%
•
31 day 1st treatment - 96%
•
31 day subsequent
surgery – 94%
surgery-94%
•
31 day subsequent
drugs – 98%
drugs-98%
•
31 day subsequent
radiotherapy – 94%
radiotherapy-94%
•
62 day (GP) referral to 1st
treatment – 85%
treatment-85%
•
62 day
(screening)
(screening )
referral to 1st
treatment – 90%
treatment-90%
•
62 day upgrade to 1st treatment
–
locally agreed standard
In addition this access and use of data will be key in delivering the new 28 day faster diagnosis standard being
introduced from 2020
introduced from April 2021 (delayed from April 2020). Trusts are asked to ensure high level of data completeness for this item in 2019/20.
[1 paragraph unchanged]
This access and resulting analysis will enable Cancer Alliances to undertake local analysis beyond the Cancer
Waiting Times operational standards to support improvements to Cancer patients pathways beyond those already achieved by improving performance against standard set. This could include reviewing times between treatments, or treatment rates.
Waiting times operational standards to support improvements to Cancer patients pathways beyond those already achieved by improving performance against standard set. This could include reviewing times between treatments, or treatment rates.
The overall aim of this type of additional analysis would be to support improvements to Cancer
patient’s
patients
survival and experience.
The Cancer Taskforce recommendation set out a number of ambitions to be met nationally and locally by 2020 including improving 1 year survival for Cancer to 75%, and improving the proportions of patients staged 1 or 2 to 62%. For both of these improvements to the diagnostic and treatment pathways are key, and require Cancer Alliances to be able to analyse the Cancer Waiting Times dataset to identify sub-optimum pathways and resulting improvements.
The Cancer Taskforce recommendation set out a number of ambitions to be met nationally and locally by 2020 including improving 1 year survival for Cancer to 75%, and improving the proportions of patients staged 1 or 2 to 62%. For both of these improvements to the diagnostic and treatment pathways are key, and require Cancer Alliances to be able to analyse the Cancer Waiting Times dataset to identify sub-optimum pathway and resulting improvements.
The overarching aim of all future analysis/outputs is to inform priorities and potential investment to improve Cancer pathways including reducing Cancer incidence and mortality, improving Cancer survival, improving patient experience, improving service efficiency and meeting national constitution standards relating to Cancer patients.
Benefits reported
Access to the
national
National
Cancer Waiting Times (CWT) data via the NHS Digital portal has given
[115 words unchanged]
to improve pathways to meet the FDS standard, and is critical to
improve
improving
challenged areas such as Colorectal, Gynaecology, and Urology
By breaking down the data, for example by sub tumour
specialty
speciality
and clinical commissioning group (CCG), the SEL Cancer Alliance can understand the volumes in throughput of patients by geography and specific tumour. In
addition
addition,
the associated waiting times can be compared to other clinical indicators, such as numbers of stage 1 and 2 cancers, as well as identifying specific
sub-specialty
sub-speciality
pathways that are outliers against the standards in specific areas of the
[28 words unchanged]
reducing inequality within the alliance geography and increasing patient equity of service.
The data is used to break down 62 day activity to look at shared performance between individual providers for SEL residents and the cancer alliance have been able to identify pathways with specific providers that are negative outliers against the timed pathways. For example in 2019/20 so far, 62 day performance in Urology for cases shared between Kings College Hospital and Guy’s and St Thomas is at 10% compliance which is the lowest shared provider pathway performance for one of the largest in volume.
NHS Digital CWT was key to SELCA demonstrating pathway outliers when looking at a range of statistical days on the pathway (median, percentile) when looking at all indicators for Prostate, Lung, and Gynaecology split by shared and internal pathways, grouped ICD10 codes, and across years and quarters to compare current performance with historical baselines. These are important pieces of work that are updated regularly to aid discussion on continuous improvement between key stakeholders
The data is used to compare treatment rates and volumes by CCG/provider trust to support projects that focus on repatriation of treatment activity between provider trusts
By looking at data at the linked provider and commissioner level we've been able to look at 2WW and treatment rate in more detail to understand the shape of recovery whilst we are still in the pandemic. We were able to identify tumour groups that were experiencing greater levels of referral into the system from outside of South East London which allowed commissioners to discuss with their counterparts why some of the non-established routes were happening and support their resolution
A recently performed deep dive into patients that have multiple two week wait referrals prior to diagnosis over variable time periods has supported the expansion of rapid diagnosis centres as part of the NHS National Cancer Long Term Plan.
DARS-NIC-204554-Y7F3H-v2.1 1 February 2021 to 31 January 2022
- Title
- Cancer Alliance access to National Cancer Waiting Times Monitoring Data Set (NCWTMDS) from the Cancer Wait Times (CWT) System
- Commercial
- No
- Sublicensing
- No
- Datasets
- 1
- Files released
- 0
Datasets: National Cancer Waiting Times Monitoring DataSet (NCWTMDS)
What changed from DARS-NIC-204554-Y7F3H-v1.8
Text removed is struck through; text added is underlined. Unchanged paragraphs are summarised rather than repeated.
| Field | Was | Became |
|---|---|---|
| Start date | 2021-02-01 | |
| End date | 2022-01-31 | |
| National Cancer Waiting Times Monitoring DataSet (NCWTMDS): legal basis | Health and Social Care Act 2012 - s261 - 'Other dissemination of information' |
Unchanged: Objective for processing, Processing activities, Expected output, Expected measurable benefits, Benefits reported.
Objective for processing
This agreement is for the South East London Cancer Alliance to access Cancer Waiting Times data. However, the Cancer Alliance is not a legal entity - its staff (and those accessing the Cancer Waiting Times data) are substantively employed by Guys and St Thomas' NHS Trust . Guys and St Thomas' NHS Trust is therefore the lead organisation, and the data controller who processes data. In this agreement, therefore, all references to accessing the data refer to the legal entity - Guys and St Thomas NHS Trust.
Improvements for Cancer patients
The independent Cancer Taskforce set out an ambitious vision for improving services, care and outcomes for everyone with Cancer: fewer people getting Cancer, more people surviving Cancer, more people having a good experience of their treatment and care, whoever they are and wherever they live, and more people being supported to live as well as possible after treatment has finished.
Cancer Alliances
Cancer Alliances, which have been set up across England, are key to driving the change needed across the country to achieve the Taskforce’s vision. Bringing together local clinical and managerial leaders from providers and commissioners who represent the whole Cancer pathway, Cancer Alliances provide the opportunity for a different way of working to improve and transform Cancer services. Cancer Alliance partners will take a whole population, whole pathway approach to improving outcomes across their geographical ‘footprints’, building on their relevant Sustainability and Transformation Plans (STPs). They will bring together influential local decision-makers and be responsible for directing funding to transform services and care across whole pathways, reducing variation in the availability of good care and treatment for all people with Cancer, and delivering continuous improvement and reduction in inequality of experience. They will particularly focus on leading transformations at scale to improve survival, early diagnosis, patient experience and long-term quality of life. Successful delivery will be shown in improvements in ratings in the Clinical Commissioning Group (CCG) Improvement and Assessment Framework (IAF), including, importantly, in the 62 day wait from referral to first treatment standard.
https://www.england.nhs.uk/publication/ccg-iaf-methodology-manual/
Cancer Wait Times (CWT) system
The Cancer Wait Times (CWT) system collects and validates the National Cancer Waiting Times Monitoring Data Set (NCWTMDS), allowing performance to be measured against operational Cancer standards. Data is validated and records merged to the same pathway to cover the period from referral to first definitive treatment for Cancer and any additional subsequent treatments.
The CWT system then determines whether the operational standard(s) that apply were met or not for the patient and the accountable provider(s). The CWT system holds NCWTMDS in a series of pre-aggregated static reports. These reports are available monthly and quarterly data (aligned with the National Statistics for Cancer Waiting Times published by NHS England). Users can query the CWT system to generate reports to feedback on the progress towards meeting these targets.
South East London Cancer Alliance
Guys and St Thomas NHS Trust will directly access the Cancer Waiting Times System on behalf of South East London Cancer Alliance across South East London, which covers a population of 1.9 million people.
Guys and St Thomas NHS Trust works with health organisations across South East London including 3 acute providers, and 6 clinical commissioning groups.
Acute Providers
•Guys and St Thomas NHS Trust
•King's College Hospital NHS Foundation Trust
•Lewisham and Greenwich NHS Trust
CCGs
• Lambeth CCG
• Southwark CCG
• Lewisham CCG
• Greenwich CCG
• Bexley CCG
• Bromley CCG
Data access
The CWT system provides one organisation (the lead organisation) representing each Cancer Alliance, with access to the following;
a) Aggregate reports (which may include unsuppressed small numbers)
b) Pseudonymised record level data - users can directly download this data from the CWT system
c) I-View Plus tool
Lead organisations will only access patient records which fall within the Cancer Alliances' footprint of responsibility based on the patients' CCG of responsibility. This Cancer Alliance is limited to South East London Cancer Patients.
A) Aggregate reports including small numbers
Aggregate data is available in the form of reports at Provider (Trust) and Clinical Commissioning Group (CCG) level.
Small numbers may be included in the aggregate data reports and are essential for analyses carried out by lead organisations.
Investigating breaches
Guys and St Thomas' NHS Trust routinely monitor performance and standards using the CWT system, particularly in relation to breaches of the 62 day wait target. Due to the large number of potential Trust/CCG combinations, breach counts could result in small numbers as in some cases there are less than 6 breaches in a whole year. Given that financial penalties are linked to target breaches counts must accurately reflect the true percentage without suppression.
Mitigating risk of re-identification
Risk of disclosure is minimised as the dataset does not include patient demographics (increasing risk of re-identification) that may allow users to identify an individual e.g. there are no age, ethnic categories or geographic breakdowns based on patient postcode.
Additionally, the aggregation categories are such that the data is not at a lesser granular level e.g. the source NCWTMDS data collects information at ICD diagnosis code level, but the CWT system aggregates at tumour group level – e.g. Head & Neck, Upper GI, lower GI, Breast etc.
B) Pseudonymised record level extracts
Lead organisations will access record level pseudonymised data which includes the system generated pseudo CWT patient ID.
Any record level data extracted from the system will not be processed outside of the authorised users of the system.
C) i-View Plus
iView Plus uses cube functionality to allow lead organisations to produce graphs, charts and tabulations from the data through the construction of queries. The data in iView plus is split by operational standard being measured and can then be analysed against a range of dimensions collected in the data and measures such as count, percentage and median. The outputs of iView Plus are aggregate, and no record level data can be obtained, however some queries may result in small numbers and these currently have limited disclosure control applied, see A) for further explanation.
iView Plus holds published data, the lowest organisational granularity is trust level, data can also be aggregated to CCG level and other health hierarchies.
Guys and St Thomas' NHS Trust will use the data to both monitor and improve performance against the Cancer Waiting Time standards and to inform wider Cancer pathway improvements.
Guys and St Thomas' NHS Trust use of the data will fall into two separate categories, each requiring different levels of suppression, and onward sharing both within the Cancer Alliance and with wider NHS stakeholders;
Purpose One - Aggregate local reports
Generation of routine Cancer Waiting Times reports at Provider (Trust) or CCG level. Guys and St Thomas' NHS Trust will access a summary of the totals for the Providers (Trust) and CCG's that are treating cancer patients where they have a commissioning responsibility for that patient (based on the CCG they are aligned to). This analysis would then be shared with the providers and commissioners and used to inform service improvement by providing benchmarked comparable data. The format of this report would be in a tabulated or graphical form (i.e. not record level) but may contain small numbers. An example of where small numbers would not be suppressed would be in relation to cases of breaches against a standard where small numbers would be essential to ensure the report is meaningful.
Examples of this type of analysis include:
a. Comparative Cancer Waiting Times performance at tumour group and individual tumour site (i.e. ICD10 code) level for Trusts and CCGs across the geography
b. Analysis of Cancer Waiting Times performance by treatment modality
c. Grouping length of waits for standards
d. Analysis of free text and derived breach reason fields to identify trends in reasons for delays
e. To provide assurance through comparative analysis (e.g. orphan record identification, active monitoring proportions and validation of waiting list adjustments entered)
f. Analysis of flows of patients including analysis by provider trust site
g. Reviewing waits between surgery and radiotherapy for Head and Neck Cancer patients with a maximum recommended wait of 6 weeks
h. Reviewing routes to diagnosis of patients
i. Quantifying treatment volumes by provider organisation including analysis treatment rates
Purpose Two - Sharing of record level data (including free text breach reasons) with providers and commissioners responsible for direct patient care for that patient. This will be for local audit purposes.
The two broad purposes for this would be;
1) To support audit work
2) Investigate individual outliers to the national standards
Pathway analysis will be undertaken, identifying trends in reasons for breaches. The analysis will inform system wide pathway improvements and compliance to the national standards. Examples of potential changes to achieve this could be to support trusts in additional resources and processes and also to facilitate discuss between trusts for example in reaching agreement for diagnostics between trusts.
Examples of the types of reasons for this include;
a. Patients waiting excessively long period of time to seen of received treatment
b. Free text breach reasons identifying areas of concern which require more detail or clarification from provider
c. Identification of 28 day standard exceptions - National guidance states patients who are diagnosed with cancer should be informed face to face, this would highlights numbers of patients who are not told in person by provider
d. Audits to review orphan records which require local providers to review local patient’s records
Record level data (pseudonymised) will be shared via NHS.net email accounts and access will be controlled by password protecting all files.
Expected output
Outputs fall into the following categories:
1) Analysis to support delivery of Cancer Waiting Times standard and identify variation, including clinical discussions to improve patient pathways
a. Comparative Cancer Waiting Times performance at tumour group and individual tumour site (i.e. ICD10 code) level for Trusts and CCGs.
b. Analysis of Cancer Waiting Times performance by treatment modality to inform discussions
c. Grouping length of waits for standards to inform discussions on going beyond constitutional standards
d. Analysis of free text and derived breach reason fields to identify trends in reasons for delays.
e. To provide assurance through comparative analysis (e.g. orphan record identification, active monitoring proportions and validation of waiting list adjustments entered)
f. Analysis of flows of patients including analysis by provider trust site
g. Outlier identification including exceptionally long waits to inform individual queries to providers
2) Cancer Waits analysis (not directly linked to constitutional standards) for the aim of identifying variation which may impact Cancer patient’s outcomes or patient experience. Examples for use of the data may include reviewing waits between surgery and radiotherapy for Head and Neck cancer patients with a maximum recommended wait of 6 weeks and using the data source to validate surgical numbers by provider trust.
The overarching aim of all future analysis/outputs is to inform priorities and potential investment to improve Cancer pathways including reducing Cancer incidence and mortality, improving Cancer survival, improving patient experience, improving service efficiency and meeting national constitution standards relating to Cancer patients.
Benefits reported
Access to the national Cancer Waiting Times (CWT) data via the NHS Digital portal has given the South East London (SEL) Cancer Alliance the ability to access granular CWT data with immediacy which has been particularly beneficial for the faster diagnosis standard (FDS) data from the start of the financial year. This has allowed the South East London Cancer Alliance to immediately understand performance and drivers, using locally developed dashboarding leveraging off the national CWT data, across South East London (SEL). This has allowed an understanding for areas of focus for the Cancer Alliance FDS Implementation Lead, which has led to improvements in performance in Breast and Head and Neck pathways and local discussion with both trusts and commissioners via the cancer alliance infrastructure (tumour level boards, provider boards) on how to improve pathways to meet the FDS standard, and is critical to improve challenged areas such as Colorectal, Gynaecology, and Urology
By breaking down the data, for example by sub tumour specialty and clinical commissioning group (CCG), the SEL Cancer Alliance can understand the volumes in throughput of patients by geography and specific tumour. In addition the associated waiting times can be compared to other clinical indicators, such as numbers of stage 1 and 2 cancers, as well as identifying specific sub-specialty pathways that are outliers against the standards in specific areas of the alliance geography, and can identify disparity in performance between SEL providers for Urology cancer. Using CWT data can identify areas of inequality, ensure tumour level work plans include reducing inequality within the alliance geography and increasing patient equity of service.
The data is used to break down 62 day activity to look at shared performance between individual providers for SEL residents and the cancer alliance have been able to identify pathways with specific providers that are negative outliers against the timed pathways. For example in 2019/20 so far, 62 day performance in Urology for cases shared between Kings College Hospital and Guy’s and St Thomas is at 10% compliance which is the lowest shared provider pathway performance for one of the largest in volume.
The data is used to compare treatment rates and volumes by CCG/provider trust to support projects that focus on repatriation of treatment activity between provider trusts
A recently performed deep dive into patients that have multiple two week wait referrals prior to diagnosis over variable time periods has supported the expansion of rapid diagnosis centres as part of the NHS National Cancer Long Term Plan.
DARS-NIC-204554-Y7F3H-v1.8 1 February 2020 to 31 January 2021
- Title
- Cancer Alliance access to National Cancer Waiting Times Monitoring Data Set (NCWTMDS) from the Cancer Wait Times (CWT) System
- Commercial
- No
- Sublicensing
- No
- Datasets
- 1
- Files released
- 0
Datasets: National Cancer Waiting Times Monitoring DataSet (NCWTMDS)
What changed from DARS-NIC-204554-Y7F3H-v0.2
Text removed is struck through; text added is underlined. Unchanged paragraphs are summarised rather than repeated.
| Field | Was | Became |
|---|---|---|
| Applicant organisation | SOUTH EAST LONDON CANCER ALLIANCE | |
| Organisation type | Network | |
| Start date | 2020-02-01 | |
| End date | 2021-01-31 | |
| National Cancer Waiting Times Monitoring DataSet (NCWTMDS): sensitivity | Sensitive |
Benefits reported
Yielded Benefits is not a requirement for new applications.
Access to the national Cancer Waiting Times (CWT) data via the NHS Digital portal has given the South East London (SEL) Cancer Alliance the ability to access granular CWT data with immediacy which has been particularly beneficial for the faster diagnosis standard (FDS) data from the start of the financial year. This has allowed the South East London Cancer Alliance to immediately understand performance and drivers, using locally developed dashboarding leveraging off the national CWT data, across South East London (SEL). This has allowed an understanding for areas of focus for the Cancer Alliance FDS Implementation Lead, which has led to improvements in performance in Breast and Head and Neck pathways and local discussion with both trusts and commissioners via the cancer alliance infrastructure (tumour level boards, provider boards) on how to improve pathways to meet the FDS standard, and is critical to improve challenged areas such as Colorectal, Gynaecology, and Urology
By breaking down the data, for example by sub tumour specialty and clinical commissioning group (CCG), the SEL Cancer Alliance can understand the volumes in throughput of patients by geography and specific tumour. In addition the associated waiting times can be compared to other clinical indicators, such as numbers of stage 1 and 2 cancers, as well as identifying specific sub-specialty pathways that are outliers against the standards in specific areas of the alliance geography, and can identify disparity in performance between SEL providers for Urology cancer. Using CWT data can identify areas of inequality, ensure tumour level work plans include reducing inequality within the alliance geography and increasing patient equity of service.
The data is used to break down 62 day activity to look at shared performance between individual providers for SEL residents and the cancer alliance have been able to identify pathways with specific providers that are negative outliers against the timed pathways. For example in 2019/20 so far, 62 day performance in Urology for cases shared between Kings College Hospital and Guy’s and St Thomas is at 10% compliance which is the lowest shared provider pathway performance for one of the largest in volume.
The data is used to compare treatment rates and volumes by CCG/provider trust to support projects that focus on repatriation of treatment activity between provider trusts
A recently performed deep dive into patients that have multiple two week wait referrals prior to diagnosis over variable time periods has supported the expansion of rapid diagnosis centres as part of the NHS National Cancer Long Term Plan.
Unchanged: Objective for processing, Processing activities, Expected output, Expected measurable benefits.
Objective for processing
This agreement is for the South East London Cancer Alliance to access Cancer Waiting Times data. However, the Cancer Alliance is not a legal entity - its staff (and those accessing the Cancer Waiting Times data) are substantively employed by Guys and St Thomas' NHS Trust . Guys and St Thomas' NHS Trust is therefore the lead organisation, and the data controller who processes data. In this agreement, therefore, all references to accessing the data refer to the legal entity - Guys and St Thomas NHS Trust.
Improvements for Cancer patients
The independent Cancer Taskforce set out an ambitious vision for improving services, care and outcomes for everyone with Cancer: fewer people getting Cancer, more people surviving Cancer, more people having a good experience of their treatment and care, whoever they are and wherever they live, and more people being supported to live as well as possible after treatment has finished.
Cancer Alliances
Cancer Alliances, which have been set up across England, are key to driving the change needed across the country to achieve the Taskforce’s vision. Bringing together local clinical and managerial leaders from providers and commissioners who represent the whole Cancer pathway, Cancer Alliances provide the opportunity for a different way of working to improve and transform Cancer services. Cancer Alliance partners will take a whole population, whole pathway approach to improving outcomes across their geographical ‘footprints’, building on their relevant Sustainability and Transformation Plans (STPs). They will bring together influential local decision-makers and be responsible for directing funding to transform services and care across whole pathways, reducing variation in the availability of good care and treatment for all people with Cancer, and delivering continuous improvement and reduction in inequality of experience. They will particularly focus on leading transformations at scale to improve survival, early diagnosis, patient experience and long-term quality of life. Successful delivery will be shown in improvements in ratings in the Clinical Commissioning Group (CCG) Improvement and Assessment Framework (IAF), including, importantly, in the 62 day wait from referral to first treatment standard.
https://www.england.nhs.uk/publication/ccg-iaf-methodology-manual/
Cancer Wait Times (CWT) system
The Cancer Wait Times (CWT) system collects and validates the National Cancer Waiting Times Monitoring Data Set (NCWTMDS), allowing performance to be measured against operational Cancer standards. Data is validated and records merged to the same pathway to cover the period from referral to first definitive treatment for Cancer and any additional subsequent treatments.
The CWT system then determines whether the operational standard(s) that apply were met or not for the patient and the accountable provider(s). The CWT system holds NCWTMDS in a series of pre-aggregated static reports. These reports are available monthly and quarterly data (aligned with the National Statistics for Cancer Waiting Times published by NHS England). Users can query the CWT system to generate reports to feedback on the progress towards meeting these targets.
South East London Cancer Alliance
Guys and St Thomas NHS Trust will directly access the Cancer Waiting Times System on behalf of South East London Cancer Alliance across South East London, which covers a population of 1.9 million people.
Guys and St Thomas NHS Trust works with health organisations across South East London including 3 acute providers, and 6 clinical commissioning groups.
Acute Providers
•Guys and St Thomas NHS Trust
•King's College Hospital NHS Foundation Trust
•Lewisham and Greenwich NHS Trust
CCGs
• Lambeth CCG
• Southwark CCG
• Lewisham CCG
• Greenwich CCG
• Bexley CCG
• Bromley CCG
Data access
The CWT system provides one organisation (the lead organisation) representing each Cancer Alliance, with access to the following;
a) Aggregate reports (which may include unsuppressed small numbers)
b) Pseudonymised record level data - users can directly download this data from the CWT system
c) I-View Plus tool
Lead organisations will only access patient records which fall within the Cancer Alliances' footprint of responsibility based on the patients' CCG of responsibility. This Cancer Alliance is limited to South East London Cancer Patients.
A) Aggregate reports including small numbers
Aggregate data is available in the form of reports at Provider (Trust) and Clinical Commissioning Group (CCG) level.
Small numbers may be included in the aggregate data reports and are essential for analyses carried out by lead organisations.
Investigating breaches
Guys and St Thomas' NHS Trust routinely monitor performance and standards using the CWT system, particularly in relation to breaches of the 62 day wait target. Due to the large number of potential Trust/CCG combinations, breach counts could result in small numbers as in some cases there are less than 6 breaches in a whole year. Given that financial penalties are linked to target breaches counts must accurately reflect the true percentage without suppression.
Mitigating risk of re-identification
Risk of disclosure is minimised as the dataset does not include patient demographics (increasing risk of re-identification) that may allow users to identify an individual e.g. there are no age, ethnic categories or geographic breakdowns based on patient postcode.
Additionally, the aggregation categories are such that the data is not at a lesser granular level e.g. the source NCWTMDS data collects information at ICD diagnosis code level, but the CWT system aggregates at tumour group level – e.g. Head & Neck, Upper GI, lower GI, Breast etc.
B) Pseudonymised record level extracts
Lead organisations will access record level pseudonymised data which includes the system generated pseudo CWT patient ID.
Any record level data extracted from the system will not be processed outside of the authorised users of the system.
C) i-View Plus
iView Plus uses cube functionality to allow lead organisations to produce graphs, charts and tabulations from the data through the construction of queries. The data in iView plus is split by operational standard being measured and can then be analysed against a range of dimensions collected in the data and measures such as count, percentage and median. The outputs of iView Plus are aggregate, and no record level data can be obtained, however some queries may result in small numbers and these currently have limited disclosure control applied, see A) for further explanation.
iView Plus holds published data, the lowest organisational granularity is trust level, data can also be aggregated to CCG level and other health hierarchies.
Guys and St Thomas' NHS Trust will use the data to both monitor and improve performance against the Cancer Waiting Time standards and to inform wider Cancer pathway improvements.
Guys and St Thomas' NHS Trust use of the data will fall into two separate categories, each requiring different levels of suppression, and onward sharing both within the Cancer Alliance and with wider NHS stakeholders;
Purpose One - Aggregate local reports
Generation of routine Cancer Waiting Times reports at Provider (Trust) or CCG level. Guys and St Thomas' NHS Trust will access a summary of the totals for the Providers (Trust) and CCG's that are treating cancer patients where they have a commissioning responsibility for that patient (based on the CCG they are aligned to). This analysis would then be shared with the providers and commissioners and used to inform service improvement by providing benchmarked comparable data. The format of this report would be in a tabulated or graphical form (i.e. not record level) but may contain small numbers. An example of where small numbers would not be suppressed would be in relation to cases of breaches against a standard where small numbers would be essential to ensure the report is meaningful.
Examples of this type of analysis include:
a. Comparative Cancer Waiting Times performance at tumour group and individual tumour site (i.e. ICD10 code) level for Trusts and CCGs across the geography
b. Analysis of Cancer Waiting Times performance by treatment modality
c. Grouping length of waits for standards
d. Analysis of free text and derived breach reason fields to identify trends in reasons for delays
e. To provide assurance through comparative analysis (e.g. orphan record identification, active monitoring proportions and validation of waiting list adjustments entered)
f. Analysis of flows of patients including analysis by provider trust site
g. Reviewing waits between surgery and radiotherapy for Head and Neck Cancer patients with a maximum recommended wait of 6 weeks
h. Reviewing routes to diagnosis of patients
i. Quantifying treatment volumes by provider organisation including analysis treatment rates
Purpose Two - Sharing of record level data (including free text breach reasons) with providers and commissioners responsible for direct patient care for that patient. This will be for local audit purposes.
The two broad purposes for this would be;
1) To support audit work
2) Investigate individual outliers to the national standards
Pathway analysis will be undertaken, identifying trends in reasons for breaches. The analysis will inform system wide pathway improvements and compliance to the national standards. Examples of potential changes to achieve this could be to support trusts in additional resources and processes and also to facilitate discuss between trusts for example in reaching agreement for diagnostics between trusts.
Examples of the types of reasons for this include;
a. Patients waiting excessively long period of time to seen of received treatment
b. Free text breach reasons identifying areas of concern which require more detail or clarification from provider
c. Identification of 28 day standard exceptions - National guidance states patients who are diagnosed with cancer should be informed face to face, this would highlights numbers of patients who are not told in person by provider
d. Audits to review orphan records which require local providers to review local patient’s records
Record level data (pseudonymised) will be shared via NHS.net email accounts and access will be controlled by password protecting all files.
Expected output
Outputs fall into the following categories:
1) Analysis to support delivery of Cancer Waiting Times standard and identify variation, including clinical discussions to improve patient pathways
a. Comparative Cancer Waiting Times performance at tumour group and individual tumour site (i.e. ICD10 code) level for Trusts and CCGs.
b. Analysis of Cancer Waiting Times performance by treatment modality to inform discussions
c. Grouping length of waits for standards to inform discussions on going beyond constitutional standards
d. Analysis of free text and derived breach reason fields to identify trends in reasons for delays.
e. To provide assurance through comparative analysis (e.g. orphan record identification, active monitoring proportions and validation of waiting list adjustments entered)
f. Analysis of flows of patients including analysis by provider trust site
g. Outlier identification including exceptionally long waits to inform individual queries to providers
2) Cancer Waits analysis (not directly linked to constitutional standards) for the aim of identifying variation which may impact Cancer patient’s outcomes or patient experience. Examples for use of the data may include reviewing waits between surgery and radiotherapy for Head and Neck cancer patients with a maximum recommended wait of 6 weeks and using the data source to validate surgical numbers by provider trust.
The overarching aim of all future analysis/outputs is to inform priorities and potential investment to improve Cancer pathways including reducing Cancer incidence and mortality, improving Cancer survival, improving patient experience, improving service efficiency and meeting national constitution standards relating to Cancer patients.
Benefits reported
Access to the national Cancer Waiting Times (CWT) data via the NHS Digital portal has given the South East London (SEL) Cancer Alliance the ability to access granular CWT data with immediacy which has been particularly beneficial for the faster diagnosis standard (FDS) data from the start of the financial year. This has allowed the South East London Cancer Alliance to immediately understand performance and drivers, using locally developed dashboarding leveraging off the national CWT data, across South East London (SEL). This has allowed an understanding for areas of focus for the Cancer Alliance FDS Implementation Lead, which has led to improvements in performance in Breast and Head and Neck pathways and local discussion with both trusts and commissioners via the cancer alliance infrastructure (tumour level boards, provider boards) on how to improve pathways to meet the FDS standard, and is critical to improve challenged areas such as Colorectal, Gynaecology, and Urology
By breaking down the data, for example by sub tumour specialty and clinical commissioning group (CCG), the SEL Cancer Alliance can understand the volumes in throughput of patients by geography and specific tumour. In addition the associated waiting times can be compared to other clinical indicators, such as numbers of stage 1 and 2 cancers, as well as identifying specific sub-specialty pathways that are outliers against the standards in specific areas of the alliance geography, and can identify disparity in performance between SEL providers for Urology cancer. Using CWT data can identify areas of inequality, ensure tumour level work plans include reducing inequality within the alliance geography and increasing patient equity of service.
The data is used to break down 62 day activity to look at shared performance between individual providers for SEL residents and the cancer alliance have been able to identify pathways with specific providers that are negative outliers against the timed pathways. For example in 2019/20 so far, 62 day performance in Urology for cases shared between Kings College Hospital and Guy’s and St Thomas is at 10% compliance which is the lowest shared provider pathway performance for one of the largest in volume.
The data is used to compare treatment rates and volumes by CCG/provider trust to support projects that focus on repatriation of treatment activity between provider trusts
A recently performed deep dive into patients that have multiple two week wait referrals prior to diagnosis over variable time periods has supported the expansion of rapid diagnosis centres as part of the NHS National Cancer Long Term Plan.
DARS-NIC-204554-Y7F3H-v0.2 1 February 2019 to 31 January 2020
- Title
- Cancer Alliance access to National Cancer Waiting Times Monitoring Data Set (NCWTMDS) from the Cancer Wait Times (CWT) System
- Commercial
- No
- Sublicensing
- No
- Datasets
- 1
- Files released
- 0
Datasets: National Cancer Waiting Times Monitoring DataSet (NCWTMDS)
Objective for processing
This agreement is for the South East London Cancer Alliance to access Cancer Waiting Times data. However, the Cancer Alliance is not a legal entity - its staff (and those accessing the Cancer Waiting Times data) are substantively employed by Guys and St Thomas' NHS Trust . Guys and St Thomas' NHS Trust is therefore the lead organisation, and the data controller who processes data. In this agreement, therefore, all references to accessing the data refer to the legal entity - Guys and St Thomas NHS Trust.
Improvements for Cancer patients
The independent Cancer Taskforce set out an ambitious vision for improving services, care and outcomes for everyone with Cancer: fewer people getting Cancer, more people surviving Cancer, more people having a good experience of their treatment and care, whoever they are and wherever they live, and more people being supported to live as well as possible after treatment has finished.
Cancer Alliances
Cancer Alliances, which have been set up across England, are key to driving the change needed across the country to achieve the Taskforce’s vision. Bringing together local clinical and managerial leaders from providers and commissioners who represent the whole Cancer pathway, Cancer Alliances provide the opportunity for a different way of working to improve and transform Cancer services. Cancer Alliance partners will take a whole population, whole pathway approach to improving outcomes across their geographical ‘footprints’, building on their relevant Sustainability and Transformation Plans (STPs). They will bring together influential local decision-makers and be responsible for directing funding to transform services and care across whole pathways, reducing variation in the availability of good care and treatment for all people with Cancer, and delivering continuous improvement and reduction in inequality of experience. They will particularly focus on leading transformations at scale to improve survival, early diagnosis, patient experience and long-term quality of life. Successful delivery will be shown in improvements in ratings in the Clinical Commissioning Group (CCG) Improvement and Assessment Framework (IAF), including, importantly, in the 62 day wait from referral to first treatment standard.
https://www.england.nhs.uk/publication/ccg-iaf-methodology-manual/
Cancer Wait Times (CWT) system
The Cancer Wait Times (CWT) system collects and validates the National Cancer Waiting Times Monitoring Data Set (NCWTMDS), allowing performance to be measured against operational Cancer standards. Data is validated and records merged to the same pathway to cover the period from referral to first definitive treatment for Cancer and any additional subsequent treatments.
The CWT system then determines whether the operational standard(s) that apply were met or not for the patient and the accountable provider(s). The CWT system holds NCWTMDS in a series of pre-aggregated static reports. These reports are available monthly and quarterly data (aligned with the National Statistics for Cancer Waiting Times published by NHS England). Users can query the CWT system to generate reports to feedback on the progress towards meeting these targets.
South East London Cancer Alliance
Guys and St Thomas NHS Trust will directly access the Cancer Waiting Times System on behalf of South East London Cancer Alliance across South East London, which covers a population of 1.9 million people.
Guys and St Thomas NHS Trust works with health organisations across South East London including 3 acute providers, and 6 clinical commissioning groups.
Acute Providers
•Guys and St Thomas NHS Trust
•King's College Hospital NHS Foundation Trust
•Lewisham and Greenwich NHS Trust
CCGs
• Lambeth CCG
• Southwark CCG
• Lewisham CCG
• Greenwich CCG
• Bexley CCG
• Bromley CCG
Data access
The CWT system provides one organisation (the lead organisation) representing each Cancer Alliance, with access to the following;
a) Aggregate reports (which may include unsuppressed small numbers)
b) Pseudonymised record level data - users can directly download this data from the CWT system
c) I-View Plus tool
Lead organisations will only access patient records which fall within the Cancer Alliances' footprint of responsibility based on the patients' CCG of responsibility. This Cancer Alliance is limited to South East London Cancer Patients.
A) Aggregate reports including small numbers
Aggregate data is available in the form of reports at Provider (Trust) and Clinical Commissioning Group (CCG) level.
Small numbers may be included in the aggregate data reports and are essential for analyses carried out by lead organisations.
Investigating breaches
Guys and St Thomas' NHS Trust routinely monitor performance and standards using the CWT system, particularly in relation to breaches of the 62 day wait target. Due to the large number of potential Trust/CCG combinations, breach counts could result in small numbers as in some cases there are less than 6 breaches in a whole year. Given that financial penalties are linked to target breaches counts must accurately reflect the true percentage without suppression.
Mitigating risk of re-identification
Risk of disclosure is minimised as the dataset does not include patient demographics (increasing risk of re-identification) that may allow users to identify an individual e.g. there are no age, ethnic categories or geographic breakdowns based on patient postcode.
Additionally, the aggregation categories are such that the data is not at a lesser granular level e.g. the source NCWTMDS data collects information at ICD diagnosis code level, but the CWT system aggregates at tumour group level – e.g. Head & Neck, Upper GI, lower GI, Breast etc.
B) Pseudonymised record level extracts
Lead organisations will access record level pseudonymised data which includes the system generated pseudo CWT patient ID.
Any record level data extracted from the system will not be processed outside of the authorised users of the system.
C) i-View Plus
iView Plus uses cube functionality to allow lead organisations to produce graphs, charts and tabulations from the data through the construction of queries. The data in iView plus is split by operational standard being measured and can then be analysed against a range of dimensions collected in the data and measures such as count, percentage and median. The outputs of iView Plus are aggregate, and no record level data can be obtained, however some queries may result in small numbers and these currently have limited disclosure control applied, see A) for further explanation.
iView Plus holds published data, the lowest organisational granularity is trust level, data can also be aggregated to CCG level and other health hierarchies.
Guys and St Thomas' NHS Trust will use the data to both monitor and improve performance against the Cancer Waiting Time standards and to inform wider Cancer pathway improvements.
Guys and St Thomas' NHS Trust use of the data will fall into two separate categories, each requiring different levels of suppression, and onward sharing both within the Cancer Alliance and with wider NHS stakeholders;
Purpose One - Aggregate local reports
Generation of routine Cancer Waiting Times reports at Provider (Trust) or CCG level. Guys and St Thomas' NHS Trust will access a summary of the totals for the Providers (Trust) and CCG's that are treating cancer patients where they have a commissioning responsibility for that patient (based on the CCG they are aligned to). This analysis would then be shared with the providers and commissioners and used to inform service improvement by providing benchmarked comparable data. The format of this report would be in a tabulated or graphical form (i.e. not record level) but may contain small numbers. An example of where small numbers would not be suppressed would be in relation to cases of breaches against a standard where small numbers would be essential to ensure the report is meaningful.
Examples of this type of analysis include:
a. Comparative Cancer Waiting Times performance at tumour group and individual tumour site (i.e. ICD10 code) level for Trusts and CCGs across the geography
b. Analysis of Cancer Waiting Times performance by treatment modality
c. Grouping length of waits for standards
d. Analysis of free text and derived breach reason fields to identify trends in reasons for delays
e. To provide assurance through comparative analysis (e.g. orphan record identification, active monitoring proportions and validation of waiting list adjustments entered)
f. Analysis of flows of patients including analysis by provider trust site
g. Reviewing waits between surgery and radiotherapy for Head and Neck Cancer patients with a maximum recommended wait of 6 weeks
h. Reviewing routes to diagnosis of patients
i. Quantifying treatment volumes by provider organisation including analysis treatment rates
Purpose Two - Sharing of record level data (including free text breach reasons) with providers and commissioners responsible for direct patient care for that patient. This will be for local audit purposes.
The two broad purposes for this would be;
1) To support audit work
2) Investigate individual outliers to the national standards
Pathway analysis will be undertaken, identifying trends in reasons for breaches. The analysis will inform system wide pathway improvements and compliance to the national standards. Examples of potential changes to achieve this could be to support trusts in additional resources and processes and also to facilitate discuss between trusts for example in reaching agreement for diagnostics between trusts.
Examples of the types of reasons for this include;
a. Patients waiting excessively long period of time to seen of received treatment
b. Free text breach reasons identifying areas of concern which require more detail or clarification from provider
c. Identification of 28 day standard exceptions - National guidance states patients who are diagnosed with cancer should be informed face to face, this would highlights numbers of patients who are not told in person by provider
d. Audits to review orphan records which require local providers to review local patient’s records
Record level data (pseudonymised) will be shared via NHS.net email accounts and access will be controlled by password protecting all files.
Expected output
Outputs fall into the following categories:
1) Analysis to support delivery of Cancer Waiting Times standard and identify variation, including clinical discussions to improve patient pathways
a. Comparative Cancer Waiting Times performance at tumour group and individual tumour site (i.e. ICD10 code) level for Trusts and CCGs.
b. Analysis of Cancer Waiting Times performance by treatment modality to inform discussions
c. Grouping length of waits for standards to inform discussions on going beyond constitutional standards
d. Analysis of free text and derived breach reason fields to identify trends in reasons for delays.
e. To provide assurance through comparative analysis (e.g. orphan record identification, active monitoring proportions and validation of waiting list adjustments entered)
f. Analysis of flows of patients including analysis by provider trust site
g. Outlier identification including exceptionally long waits to inform individual queries to providers
2) Cancer Waits analysis (not directly linked to constitutional standards) for the aim of identifying variation which may impact Cancer patient’s outcomes or patient experience. Examples for use of the data may include reviewing waits between surgery and radiotherapy for Head and Neck cancer patients with a maximum recommended wait of 6 weeks and using the data source to validate surgical numbers by provider trust.
The overarching aim of all future analysis/outputs is to inform priorities and potential investment to improve Cancer pathways including reducing Cancer incidence and mortality, improving Cancer survival, improving patient experience, improving service efficiency and meeting national constitution standards relating to Cancer patients.
Benefits reported
Yielded Benefits is not a requirement for new applications.
Register history
When this agreement appeared in, or was edited in, each monthly edition of the register. Built by comparing every edition this site holds, the earliest of which is July 2021.
-
July 2021 —
already listed in the earliest edition this site holds, so it may be older. 3 versions: DARS-NIC-204554-Y7F3H-v0.2, DARS-NIC-204554-Y7F3H-v1.8, DARS-NIC-204554-Y7F3H-v2.1
-
March 2022
1 version added: DARS-NIC-204554-Y7F3H-v3.2
-
December 2022
Register-wide edit DARS-NIC-204554-Y7F3H-v0.2, DARS-NIC-204554-Y7F3H-v1.8 — Datasets: legal basis: “
s261(1) and” taken out. Made to 639 agreements in this edition, so it is reported once, on the changes page, and not counted as an amendment of this agreement. -
March 2023
Amended DARS-NIC-204554-Y7F3H-v3.2
- Expected output:
reworded
Show the change
[10 paragraphs unchanged] 2) Cancer Waits analysis (not directly linked to constitutional standards) for the aim of identifying variation which may impact Cancer
patientspatients outcomes or patient experience. Examples for use of the data may include [20 words unchanged] and using the data source to validate surgical numbers by provider trust.
- Expected output:
reworded
"Amended in place" means NHS England changed the record without issuing a new version number. The register publishes no changelog for those edits; this site infers them by comparing editions. An edit is attributed to the edition it first appears in, not to the date it was made.
Cite this page
NHS England (2026) Data Uses Register, September 2026 edition, agreement DARS-NIC-204554-Y7F3H, “Cancer Alliance access to National Cancer Waiting Times Monitoring Data Set (NCWTMDS) from the Cancer Wait Times (CWT) System”. Read via NHS Data Access Explorer (unofficial), https://healthdatauses.uk/agreements/dars-nic-204554-y7f3h/ (accessed [date]).
This address stays the same, but the page is rebuilt with each monthly edition, so the citation names the edition it shows. Every edition's data is kept in the facts store.
Source: datausesregister_september2026.xlsx, September 2026 edition of the NHS England Data Uses Register. Search that workbook for DARS-NIC-204554-Y7F3H to see the original rows.